WASHINGTON, DC and Blue Bell, PA (January 7, 2013)—The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced a follow-on collaboration to advance ...
Trial Now Enrolling at University of Wisconsin, with Additional Centers to Follow MADISON, WI, USA I June 23, 2014 I Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company, ...
MADISON, Wis.--(BUSINESS WIRE)--Madison Vaccines Incorporated (MVI) today announced dosing has begun in a combination trial for MVI-816 (pTVG-HP), its lead prostate cancer vaccine, paired with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results